Gao X, Zhou B, Feng X, Ji Z, Li Q, Liu H
Mol Med. 2025; 31(1):89.
PMID: 40055606
PMC: 11887163.
DOI: 10.1186/s10020-025-01145-1.
Ghosh A, Stephens K, Kandiah P, Hurt R, Gilman E
Curr Gastroenterol Rep. 2025; 27(1):19.
PMID: 40047994
PMC: 11885400.
DOI: 10.1007/s11894-025-00970-y.
Yeo M, Voutsadakis I
J Clin Med. 2025; 14(4).
PMID: 40004631
PMC: 11856852.
DOI: 10.3390/jcm14041099.
Ying L, Zhang L, Chen Y, Huang C, Zhou J, Xie J
Sci Rep. 2025; 15(1):6387.
PMID: 39984646
PMC: 11845748.
DOI: 10.1038/s41598-025-90899-z.
Zheng Z, Sun X
Transl Cancer Res. 2025; 14(1):141-158.
PMID: 39974388
PMC: 11833362.
DOI: 10.21037/tcr-24-1030.
Multidimensional analysis of clinicopathological characteristics and long-term prognosis of colonic signet-ring cell carcinoma.
Liu L, Sun Y
Surg Endosc. 2025; .
PMID: 39966132
DOI: 10.1007/s00464-025-11548-0.
Decreasing Use of CT in Favor of Colonoscopy: A Retrospective Analysis of Post-Operative Imaging in Nonmetastatic dMMR/MSI-H Sporadic Colorectal Cancer.
Mi S, Liao Y, Kang D, Tang X, Chen G, Pan Z
Ann Surg Oncol. 2025; .
PMID: 39948309
DOI: 10.1245/s10434-025-16989-4.
Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment.
Valenzuela G, Contreras H, Marcelain K, Burotto M, Gonzalez-Montero J
Int J Mol Sci. 2025; 26(3).
PMID: 39940936
PMC: 11818086.
DOI: 10.3390/ijms26031168.
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.
Pattalachinti V, Haque E, Yousef M, Yousef A, Chowdhury S, Overman M
NPJ Precis Oncol. 2025; 9(1):38.
PMID: 39910160
PMC: 11799341.
DOI: 10.1038/s41698-025-00821-z.
Lymph node yield does not affect the cancer-specific survival of patients with T1 colorectal cancer: a population-based retrospective study of the U.S. database and a Chinese registry.
Li J, Tian R, Huang F, Cheng P, Zhao F, Zhao Z
Int J Colorectal Dis. 2025; 40(1):31.
PMID: 39909882
PMC: 11799036.
DOI: 10.1007/s00384-025-04816-x.
Risk Prediction of Myelosuppression Following First-line Chemotherapy in Colorectal Cancer.
Du Y, Liu Y, Fang R, Cai L, Song Y, Ma S
J Cancer. 2025; 16(4):1379-1396.
PMID: 39895779
PMC: 11786037.
DOI: 10.7150/jca.104412.
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment.
Crisafulli G
Genes (Basel). 2025; 16(1).
PMID: 39858618
PMC: 11765229.
DOI: 10.3390/genes16010071.
Characteristics, Treatment and Outcomes of Stage I to III Colorectal Cancer in Patients Aged over 80 Years Old.
Yeo M, Voutsadakis I
Cancers (Basel). 2025; 17(2.
PMID: 39858029
PMC: 11763545.
DOI: 10.3390/cancers17020247.
Effects of Microsatellite Instability on the Clinical and Pathological Characteristics of Colon Cancer and the Diagnostic Accuracy of Preoperative Abdominal CT Scans.
Yavuz R, Aras O, Ciyiltepe H, Dincer O, Alparslan A, Cakir T
Diagnostics (Basel). 2025; 15(2).
PMID: 39857073
PMC: 11765182.
DOI: 10.3390/diagnostics15020190.
Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer.
Guan R, Wu J, Yuan Z, Liu Z, Liu Z, Xiao Z
World J Gastroenterol. 2025; 31(3):98688.
PMID: 39839894
PMC: 11684163.
DOI: 10.3748/wjg.v31.i3.98688.
Recent advances in self-targeting natural product-based nanomedicines.
Liu H, Jin X, Liu S, Liu X, Pei X, Sun K
J Nanobiotechnology. 2025; 23(1):31.
PMID: 39833846
PMC: 11749302.
DOI: 10.1186/s12951-025-03092-9.
Current status of postoperative morbidity following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis: a prospective single-center observational study.
Jo J, Suh J, Lee S, Namgung H, Park D
Ann Surg Treat Res. 2025; 108(1):12-19.
PMID: 39823036
PMC: 11735167.
DOI: 10.4174/astr.2025.108.1.12.
Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study.
Lam K, Li K, Leung R, Tang V, Yau T
Adv Ther. 2025; 42(2):1222-1236.
PMID: 39804541
PMC: 11787203.
DOI: 10.1007/s12325-024-03077-4.
Self-Expandable Metal Stents for Obstructing Colon Cancer and Extracolonic Cancer: A Review of Latest Evidence.
Cardoso P, Rodrigues-Pinto E
Cancers (Basel). 2025; 17(1.
PMID: 39796716
PMC: 11719978.
DOI: 10.3390/cancers17010087.
Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer.
Pang H, Chen X, Yan M, Sun H
Precis Clin Med. 2025; 8(1):pbae033.
PMID: 39790478
PMC: 11715517.
DOI: 10.1093/pcmedi/pbae033.